U.S. markets closed

Devyser Diagnostics AB (publ) (DVYSR.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
65.60+0.20 (+0.31%)
At close: 05:29PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close65.40
Bid64.00 x N/A
Ask65.40 x N/A
Day's Range65.40 - 67.00
52 Week Range58.60 - 97.20
Avg. Volume6,811
Market Cap1.102B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.60
Earnings DateNov 09, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est117.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for DVYSR.ST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Devyser and Thermo Fisher Scientific collaborate to promote laboratory services to advance pharmaceutical research

      Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services. The goal is to partner with pharmaceutical companies to support their development projects utilising Devyser's unique assays in its CLIA-certified laboratory.

    • PR Newswire

      Devyser Diagnostics AB publishes quarterly report for the period April to June 2023

      "The second quarter of the year saw an improvement in EBIT compared with recent quarters, continued high gross margins, strong growth and an exclusive collaboration and distribution agreement with US-based Thermo Fisher Scientific. Two new oncology products and one new transplant product were launched during the quarter. Our CLIA-certified laboratory in Atlanta was inaugurated and the first patient test was carried out in this laboratory.", Fredrik Alpsten, CEO, Devyser.

    • PR Newswire

      Devyser's NGS products for monitoring of kidney and stem cell transplanted patients receive IVDR approvals

      Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted patients fulfill IVDR requirements in Europe. These tests are the first post-transplant monitoring NGS products to be approved under the new, more comprehensive regulation that came into force in May 2022 and confirm Devyser's two NGS products meet the established safety, efficacy, and quality requirements.